MD Anderson is the first institution to address the interrelated problems of theft of intellectual property, violation of ethics of NIH peer review, and researchers' failure to disclose foreign affiliations and sources of funding.
As MD Anderson investigates reports of wrongdoing by its faculty members, it does so with full understanding that the stakes are as high as it gets: the integrity of the NIH peer review system, MD Anderson's good name, and the future of cancer research.
Every year, 800 to 1,000 new patients get referred to The Tisch Cancer Insitute of Mount Sinai lung cancer specialists.
The University of Pennsylvania was planning a short-term trial for robotic mastectomies, but after an FDA advisory, investigators decided to revise that protocol to include assessment of cancer-related outcomes, said Ari Brooks, director of endocrine and oncologic surgery, director of the Integrated Breast Center at the University of Pennsylvania Health System, and professor of clinical surgery at Penn Medicine.
Robotic mastectomy deserves to be studied, because the procedure may improve cancer-related outcomes, surgeons at MD Anderson Cancer Center say.
The Breast Surgical Service at Memorial Sloan Kettering Cancer Center has decided not to adopt—or study—robotic surgical devices in mastectomies, said Laurie Kirstein, a breast surgical oncologist at MSK.
Community oncology needs to adapt to the era of precision oncology and Big Data, said Lee Schwartzberg, executive director of Memphis-based West Cancer Center, who was recently named chief medical officer of OneOncology, a partnership between three oncology practices located in Tennessee and New York.
Advocates of renewing the Cancer Prevention and Research Institute of Texas argue that the agency is a good investment for the state.
The Tomosynthesis Mammographic Imaging Screening Trial, a massive randomized trial of early detection, is asking an important question:
Matthew Ong spoke with Charles Roberts.
